Targeting self-renewal pathways in myeloid malignancies

Cell Communication and Signaling

Volumn 11, Issue 1, 2013, Pages

  Sands, William A ^a   Copland, Mhairi ^a   Wheadon, Helen ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cross talk; Hematopoietic stem cell; Leukemia; Myeloid; Self renewal; Therapy

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; ACETYLSALICYLIC ACID; ALSTERPAULLONE; ANTINEOPLASTIC AGENT; BETA CATENIN; CGP 049090; CPG 049090; CPG049090; HOX PROTEIN; ICG 001; MK 0752; NONSTEROID ANTIINFLAMMATORY AGENT; NOTCH RECEPTOR; NSC 668036; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PKF 118 310; PKF 118 744; PKF 222 815; PNU 74654; PROTEIN KINASE C; RETINOL; SEOCALCITOL; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR FOXO; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D; WNT PROTEIN; XAV 939; ZTM 000990;

ACUTE GRANULOCYTIC LEUKEMIA; BINDING AFFINITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION; GENE TARGETING; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HOX GENE; HUMAN; LEUKEMIA; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; TARGET CELL DESTRUCTION; UBIQUITINATION;

EID: 84878298113     PISSN: None     EISSN: 1478811X     Source Type: Journal    
DOI: 10.1186/1478-811X-11-33     Document Type: Review

References (113)

1. Microenvironmental targeting of Wnt/β-catenin signals for hematopoietic stem cell regulation. Il-Hoan O, Exp Opin Biol Thera 2010 10 1315 1329 10.1517/14712598.2010.504705
2. Establishment and regulation of the HSC niche: roles of osteoblastic and vascular compartments. Coskun S, Hirschi KK, Birth Defects Res 2010 90 229 242 10.1002/bdrc.20194
3. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ, Cell 2005 121 1109 1121 10.1016/j.cell.2005. 05.026 15989959 (Pubitemid 40884400)
4. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, Soneji S, Woll P, Mead A, Alford KA, Rout R, Chaudhury S, Gilkes A, Knapper S, Beldjord K, Begum S, Rose S, Geddes N, Griffiths M, Standen G, Sternberg A, Cavenagh J, Hunter H, Bowen D, Killick S, Robinson L, Price A, Macintyre E, Virgo P, Burnett A, Craddock C, Cancer Cell 2011 19 138 152 10.1016/j.ccr.2010.12.012 21251617
5. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Cozzio A, Passegué E, Ayton PM, Karsunky H, Cleary ML, Weissman IL, Genes Dev 2003 17 3029 3305 10.1101/gad.1143403 14701873 (Pubitemid 38040767)
6. Selective homing of human leukemic B-cell precursors to specific lymphohematopoietic microenvironments in SCID mice: A role for the beta 1 integrin family surface adhesion molecules VLA-4 and VLA-5. Messinger Y, Chelstrom L, Gunther R, Ukmi FM, Leuk Lymphoma 1996 23 61 69 10.3109/10428199609054803 9021687 (Pubitemid 26359943)
7. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice. Lapidot T, Kollet O, Leukemia 2002 16 1992 2003 10.1038/sj.leu.2402684 12357350 (Pubitemid 35203441)
8. Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. Tefferi A, J Cell Mol Med 2009 2 215 237
9. Recent advances in the diagnosis and classification of myeloid neoplasms - comments on the 2008 WHO. Yin CC, Medeiros LJ, Bueso-Ramos CE, Classif 2010 5 461 476
10. World Health Organization Classification, Evaluation, and Genetics of the Myeloproliferative Neoplasm Variants. Vardiman J, Hyjek E, Hematol 2011 2011 250 256 10.1182/asheducation-2011.1.250
11. Eosinophilic myeloproliferative disorders. Klion AD, Hematol Am Soc Hematol Educ Program 2011 2011 257 263 10.1182/asheducation-2011.1.257
12. Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal. Heuser M, Sly LM, Argiropoulos B, Kuchenbauer F, Lai C, Weng A, Leung M, Lin G, Brookes C, Fung S, Valk PJ, Delwel R, Löwenberg B, Krystal G, Humphries RK, Blood 2009 114 3983 3993 10.1182/blood-2009-06-227603 19667399
13. Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPα Radomska HS, Alberich-Jordà M, Will B, Gonzalez D, Delwel R, Tenen DG, J Clin Invest 2012 122 2955 2966 10.1172/JCI43354 22797303
14. Functional response of leukemic blasts to stromal cell-derived factor-1 correlates to the preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukemia. Mohle R, Schittenhelm M, Failenschmid C, Bautz F, Kratz-Albers K, Serve H, Brugger W, Kranz L, Br J Haematol 2000 110 563 572 10.1046/j.1365-2141.2000.02157.x 10997965
15. Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia? Tavor S, Petit I, Seminars in Cancer Biol 2010 20 178 185 10.1016/j.semcancer.2010.07. 001
16. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Walkley C, Olsen G, Dworkin S, Fabb SA, Swann J, McArthur GA, Westmoreland SV, Chambon P, Scadden DT, Purton LE, Cell 2007 129 1097 1110 10.1016/j.cell.2007.05.014 17574023 (Pubitemid 46908696)
17. Bone progenitor dysfunction induces myelodysplasia and secondary leukemia. Raaijmakers M, Mukherjee S, Guo S, Zhang S, Kobayashi T, Schoonmaker JA, Ebert BL, Al-Shahrour F, Hasserjian RP, Scadden EO, Aung Z, Matza M, Merkenschlager M, Lin C, Rommens JM, David T, Nature 2010 464 852 857 10.1038/nature08851 20305640
18. Leukemia stem cells. Buss AC, Ho AD, Int J Cancer 2011 129 2328 2336 10.1002/ijc.26318 21796620
19. A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caliqiuri MA, Dick JE, Nature 1994 367 645 658 10.1038/367645a0 7509044 (Pubitemid 24067706)
20. Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. Riobo NA, Lu K, Ai X, Haines GM, Emerson CP, Proc Natl Acad Sci USA 2006 103 4505 4510 10.1073/pnas.0504337103 16537363
21. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Tothova Z, Kollipara R, Huntly BJ, Lee BH, Castrillon DH, Cullen DE, McDowell EP, Lazo-Kallanian S, Williams IR, Sears S, Armstrong SA, Passegué E, DePinho RA, Gilliland DG, Cell 2007 128 325 339 10.1016/j.cell.2007.01.003 17254970 (Pubitemid 46137992)
22. FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system. Tothova Z, Gilliland DG, Cell Stem Cell 2007 1 140 152 10.1016/j.stem.2007.07.017 18371346 (Pubitemid 47215597)
23. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukemic prevention. Zhang J, Grindley JC, Yin T, Jayasinghe S, He XC, Ross JT, Haug JS, Rupp D, Porter-Westpfahl KS, Wiedemann LM, Wu H, Li L, Nature 2006 441 518 522 10.1038/nature04747 16633340 (Pubitemid 44050154)
24. mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Kalaitzidis D, Sykes SM, Wang Z, Punt N, Tang Y, Ragu C, Sinha AU, Lane SW, Souza AL, Clish CB, Anastasiou D, Gilliland DG, Scadden DT, Guertin DA, Armstrong SA, Cell Stem Cell 2012 11 429 439 10.1016/j.stem.2012.06.009 22958934
25. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M, Druker BJ, Puri KD, Ulrich RG, Giese NA, Blood 2011 117 591 594 10.1182/blood-2010-03-275305 20959606
26. Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML. Heidel FH, Bullinger L, Feng Z, Wang Z, Neff TA, Stein L, Kalaitzidis D, Lane SW, Armstrong SA, Cell Stem Cell 2012 10 412 424 10.1016/j.stem.2012.02.017 22482506
27. Mining the Wnt pathway for cancer therapeutics. Barker N, Clevers H, Nature Rev Drug Discov 2006 5 997 1014 10.1038/nrd2154 (Pubitemid 44835127)
28. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F, Bruseo C, Wood AW, Shivdasani RA, Cancer Cell 2004 5 91 102 10.1016/S1535-6108(03) 00334-9 14749129 (Pubitemid 38121599)
29. Glycogen synthase kinase 3 in MLL leukemia maintenance and targeted therapy. Wang Z, Smith KS, Murphy M, Piloto O, Somervaille TC, Cleary ML, Nature 2008 455 1205 1209 10.1038/nature07284 18806775
30. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. Coluccia AM, Vacca A, Dunach M, Mologni L, Redaelli S, Bustos VH, Benati D, Pinna LA, Gambacorti-Passerini C, EMBO J 2007 26 1456 1466 10.1038/sj.emboj.7601485 17318191 (Pubitemid 46398694)
31. Tankyrase inhibition stabilizes axin and antagonizes Wnt signaling. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S, Hild M, Shi X, Wilson CJ, Mickanin C, Myer V, Fazal A, Tomlinson R, Serluca F, Shao W, Cheng H, Shultz M, Rau C, Schirle M, Schlegl J, Ghidelli S, Fawell S, Lu C, Curtis D, Kirschner MW, Lengauer C, Finan PM, Tallarico JA, Bouwmeester T, Nature 2009 46 614 620
32. Mechanism and clinical prospects of Notch inhibitors in the therapy of haematological malignancies. Nefedova Y, Gabrilovich D, Drug Resist Update 2008 11 210 218 10.1016/j.drup.2008.09.002
33. Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3. Li K, Li Y, Wu W, Gordon WR, Chang DW, Lu M, Scoggin S, Fu T, Vien L, Histen G, Zheng J, Martin-Hollister R, Duensing T, Singh S, Blacklow SC, Yao Z, Aster JC, Zhou BB, J Biol Chem 2008 283 8046 8054 10.1074/jbc.M800170200 18182388
34. Targeting Hedgehog in Hematological Malignancies. Irvine D, Copland M, Blood 2012 119 2196 2204 10.1182/blood-2011-10-383752 22223823
35. TGF-beta-FOXO signaling maintains leukemia-initiating cells in chronic myeloid leukemia. Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y, et Nakao S, Motoyama N, Hirao A, Nature 2010 463 676 680 10.1038/nature08734 20130650
36. c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells. Waldron T, De Dominici M, Soliera AR, Audia A, Iacobucci I, Lonetti A, Martinelli G, Zhang Y, Martinez R, Hyslop T, Bender TP, Calabretta B, Leukemia 2012 26 644 653 10.1038/leu.2011.264 21960247
37. A role for Wnt signaling in self-renewal of haematopoietic stem cells. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K, Hintz L, Nusse R, Weissman IL, Nature 2003 423 409 414 10.1038/nature01593 12717450 (Pubitemid 36626987)
38. Wnt/ß-Catenin: A New Therapeutic Approach to Acute Myeloid Leukemia. Kim Y, Thanendrarajan S, Schmidt-Wolf IGH, Leukemia Research and Treatment 2011 4 2011 Article ID 428960 10.4061/2011/428960
39. The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia. Mikesch J, Steffen B, Berdel WE, Serve H, Müller-Tidow C, Leukemia 2007 21 1638 1647 10.1038/sj.leu.2404732 17554387 (Pubitemid 47086754)
40. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A, Sawyers CL, Weissman IL, N Engl J Med 2004 351 657 667 10.1056/NEJMoa040258 15306667 (Pubitemid 39063268)
41. Wnt signaling through inhibition of β-catenin degradation in an intact Axin1 complex. Li VS, Ng SS, Boersema PJ, Low TY, Karthaus WR, Gerlach JP, Mohammed S, Heck AJ, Maurice MM, Mahmoudi T, Clevers H, Cell 2012 149 1245 1256 10.1016/j.cell.2012.05.002 22682247
42. Wnt signaling and haematopoiesis:A Wnt-Wnt situation. Staal FJT, Clevers HC, Nat Rev Immunol 2005 5 21 30 10.1038/nri1529 15630426 (Pubitemid 40070328)
43. Regulation of hematopoiesis and the hematopoietic stem cell niche by Wnt signaling pathways. Nemeth MJ, Bodine DM, Cell Res 2007 17 746 758 10.1038/cr.2007.69 17768401 (Pubitemid 47409701)
44. Wnt5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. Topol L, Jiang X, Choi H, Garrett-Beal L, Carolan PJ, Yang Y, J Cell Biol 2003 162 899 808 10.1083/jcb.200303158 12952940 (Pubitemid 37087729)
45. The extracellular domain of Lrp5/6 inhibits non-canonical Wnt signaling in vivo. Bryja V, Anderson ER, Schamhony A, Esner M, Bryjová L, Biris KK, Mol Cell Biol 2009 20 924 936
46. Gene expression changes associated with progression and response in chronic myeloid leukemia. Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, Sawyers C, Shah N, Stock W, Willman CL, Friend S, Linsley PS, Proc Natl Acad Sci USA 2006 103 2794 2799 10.1073/pnas.0510423103 16477019
47. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, Zon LI, Armstrong SA, Science 2010 327 1650 1653 10.1126/science.1186624 20339075
48. β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Yeung J, Esposito MT, Gandillet A, Zeisig BB, Griessinger E, Bonnet D, So CW, Cancer Cell 2010 18 606 618 10.1016/j.ccr.2010.10.032 21156284
49. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, Lagoo A, Reya T, Cancer Cell 2007 12 528 541 10.1016/j.ccr.2007.11.003 18068630 (Pubitemid 350199070)
50. Beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Hu Y, Chen Y, Douglas L, Li S, Leukemia 2009 23 109 116 10.1038/leu.2008.262 18818703
51. Drugging The Wnt pathway: problems and progress. Garber K, JNCI J Natl Cancer Inst 2009 101 548 550 10.1093/jnci/djp084
52. TAN-1, the human homolog of the Drosophila Notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD, Sklar J, Cell 1991 66 649 661 10.1016/0092-8674(91)90111-B 1831692 (Pubitemid 121001701)
53. Expression pattern of Notch 1,2 and 3 and jagged 1 and 2 in lymphoid and stromal thymus components:distinct ligand-receptor interactions in intrathymic T cell development. Felli MP, Maroder M, Mitsiadis TA, Campese AF, Bellavia D, Vacca A, Int Immunol 1999 11 1017 1025 10.1093/intimm/11.7.1017 10383933 (Pubitemid 29338742)
54. The Notch ligand Jagged-1, influences the development of primitive hematopoietic precursor cells. Varnum-Finney B, Purton LE, Yu M, Brashem-Stein C, Flowers D, Staats S, Moore KA, Le Roux I, Mann R, Gray G, Artavanis-Tsakonas S, Bernstein ID, Blood 1998 91 4084 4091 9596653 (Pubitemid 28261969)
55. A human homologue of the Drosophila developmental gene, Notch, is expressed in CD34+ hematopoietic precursors. Milner LA, Kopan R, Martin DI, Bernstein ID, Blood 1994 83 2057 2062 7512837 (Pubitemid 24112715)
56. Modulated expression of Notch1 during thymocyte development. Hasserjian RP, Aster JC, Davi F, Weinberg DS, Sklar J, Blood 1996 88 970 976 8704256 (Pubitemid 26333321)
57. Signaling downstream of activated mammalian Notch. Jarriault S, Brou C, Logeat F, Schroeter EH, Kopan R, Israel A, Nature 1995 377 355 358 10.1038/377355a0 7566092
58. Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. Duncan AW, Rattis FM, DiMascio LN, Kongdon KL, Pazianos G, Zhao C, Mann RS, Frati L, Lendahl U, Gulino A, Screpanti I, Nat Immunol 2005 6 314 322 10.1038/ni1164 15665828 (Pubitemid 41724769)
59. Notch activation inhibits AML growth and survival: a potential therapeutic approach. Kannan S, Sutphin RM, Hall MG, Golfman LS, Fang W, Nolo RM, Akers LJ, Hammitt RA, McMurray JS, Kornblau SM, Melnick AM, Figueroa ME, Zweidler-McKay PA, J Exp Med 2013 210 321 337 10.1084/jem.20121527 23359069
60. Notch pathway activation targets AML-initiating cell homeostasis and differentiation. Lobry C, Ntziachristos P, Ndiaye-Lobry D, Oh P, Cimmino L, Zhu N, Araldi E, Hu W, Freund J, Abdel-Wahab O, Ibrahim S, Skokos D, Armstrong SA, Levine RL, Park CY, Aifantis I, J Exp Med 2013 210 301 319 10.1084/jem.20121484 23359070
61. A novel tumour-suppressor function for the Notch pathway in myeloid leukemia. Klinakis A, Lobry C, Abdel-Wahab O, Oh P, Haeno H, Buonamici S, van De Walle I, Cathelin S, Trimarchi T, Araldi E, Liu C, Ibrahim S, Beran M, Zavadil J, Efstratiadis A, Taghon T, Michor F, Levine RL, Aifantis I, Nature 2011 473 230 233 10.1038/nature09999 21562564
62. Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia. Nakahara F, Sakata-Yanagimoto M, Komeno Y, Kato N, Uchida T, Haraguchi K, Kumano K, Harada Y, Harada H, Kitaura J, Ogawa S, Kurokawa M, Kitamura T, Chiba S, Blood 2010 115 2872 2881 10.1182/blood-2009-05-222836 19861684
63. Cross-talk between Notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Rizzo P, Miao H, D'Souza G, Osipo C, Song LL, Yun J, Zhao H, Mascarenhas J, Wyatt D, Antico G, Hao L, Yao K, Rajan P, Hicks C, Siziopikou K, Selvaggi S, Bashir A, Bhandari D, Marchese A, Lendahl U, Qin JZ, Tonetti DA, Albain K, Nickoloff BJ, Miele L, Cancer Res 2008 68 5226 5235 10.1158/0008-5472.CAN-07-5744 18593923
64. Hedgehog signaling is dispensable for adult hematopoietic stem cell function. Gao J, Graves S, Koch U, Mao J, Morgan KJ, Lee BH, Kharas MG, Miller PG, Cornejo MG, Okabe R, Armstrong SA, Ghilardi N, Gould S, de Sauvage FJ, McMahon AP, Gilliland DG, Cell Stem Cell 2009 4 548 558 10.1016/j.stem.2009.03. 015 19497283
65. Hedgehog signaling is essential for maintenance of cancer stem cells in myeloid leukemia. Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J, Kwon HY, Kim J, Chute JP, Rizzieri D, Munchhof M, VanArsdale T, Beachy PA, Reya T, Nature 2009 458 776 779 10.1038/nature07737 19169242
66. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Dierks C, Beigi R, Guo GR, Zirlik K, Stegert MR, Manley P, Trussell C, Schmitt-Graeff A, Landwerlin K, Veelken H, Warmuth M, Cancer Cell 2008 14 2338 2349
67. Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells. Kobune M, Takimoto R, Murase K, Iyama S, Sato T, Kikuchi S, Kawano Y, Miyanishi K, Sato Y, Niitsu Y, Kato J, Cancer Sci 2009 100 948 955 10.1111/j.1349-7006.2009.01111.x 19245435
68. Differential expression of Sonic hedgehog and Gli1 in hematological malignancies. Bai LY, Chiu CF, Lin CW, Hsu NY, Lin CL, Lo WJ, Cao MC, Leukemia 2008 22 226 228 10.1038/sj.leu.2404978 17928882
69. Hedgehog Signaling in Hematopoiesis. Yiting L, Matsui W, Crit Rev Eukaryot Gene Expr 2010 20 129 139 10.1615/CritRevEukarGeneExpr.v20.i2.30 21133842
70. Sonic hedgehog promotes multi-drug resistance by regulation of drug transport. Sims-Mourtada J, Izzo JG, Ajani J, Chao KS, Oncogene 2007 26 5674 5679 10.1038/sj.onc.1210356 17353904 (Pubitemid 47267845)
71. Activation of the BCL2 promoter in response to Hedgehog/GLI signal is predominantly mediated by GLI2. Regl G, Kasper M, Schnider H, Eichberger T, Neill GW, Philpott MP, Esterbauer H, Hauser-Kronberger C, Frischauf AM, Aberger F, Cancer Res 2004 64 7724 7731 10.1158/0008-5472.CAN-04-1085 15520176 (Pubitemid 39446903)
72. Signaling pathways governing stem-cell fate. Blank U, Karlsson G, Karlsson S, Blood 2008 111 492 503 10.1182/blood-2007-07-075168 17914027
73. Autoimmune manifestation in the transforming growth-factor beta 1 knockout mouse. Yaswen L, Kulkarni AB, Fredrickson T, Mittleman B, Schiffman R, Payne S, Longenecker G, Mozes E, Karlsson S, Blood 1996 87 1439 1445 8608234 (Pubitemid 26056908)
74. Induced disruption of the transforming-growth factor beta type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable. Leveen P, Larsson J, Ehinger M, Cilio CM, Sundler M, Sjöstrand LJ, Holmdahl R, Karlsson S, Blood 2002 100 560 568 10.1182/blood.V100.2.560 12091349 (Pubitemid 34761120)
75. Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Bhardwaj G, Murdoch B, Wu D, Baker DP, Williams KP, Chadwick K, Ling LE, Karanu FN, Bhatia M, Nat Immunol 2001 2 172 180 10.1038/84282 11175816 (Pubitemid 33707938)
76. Transforming growth factor-beta signaling in normal and malignant hematopoiesis. Kim SJ, Letterio J, Leukemia 2003 17 1731 1737 10.1038/sj.leu.2403069 12970772 (Pubitemid 37185248)
77. Smad4 binds Hoxa9 in the cytoplasm and protects primitive hematopoietic cells against nuclear activation by Hoxa9 and leukemia transformation. Quéré R, Karlsson G, Hertwig F, Rissler M, Lindqvist B, Fioretos T, Vandenberghe P, Slovak ML, Cammenga J, Karlsson S, Blood 2011 117 5918 5930 10.1182/blood-2010-08-301879 21471525
78. BMP and Wnt Specify Hematopoietic Fate by Activation of the Cdx-Hox Pathway. Lengerke C, Schmitt S, Bowman TV, Jang IH, Maouche-Chretien L, McKinney-Freeman S, Davidson AJ, Hammerschmidt M, Rentzsch F, Green JB, Zon LI, Daley GQ, Cell Stem Cell 2008 2 72 82 10.1016/j.stem.2007.10.022 18371423
79. TGFβ/BMP inhibits the bone marrow transformation capability of Hoxa9 by repressing its DNA-binding ability. Wang N, Kim HG, Cotta CV, Wan M, Tang Y, Klug CA, Cao X, EMBO J 2006 25 1469 1480 10.1038/sj.emboj.7601037 16525506
80. Cdx4 is a direct target of the canonical Wnt pathway. Pilon N, Oh K, Sylvestre J, Bouchard N, Bouchard N, Savory J, Lohnes D, Dev Biol 2006 289 55 63 10.1016/j.ydbio.2005.10.005 16309666 (Pubitemid 41804088)
81. Cdx4 dysregulates Hox gene expression and generates acute myeloid leukemia alone and in cooperation with Meis1a in a murine model. Bansal D, Scholl C, Fröhling S, McDowell E, Lee BH, Döhner K, Ernst P, Davidson AJ, Daley GQ, Zon LI, Gilliland DG, Huntly BJ, Proc Natl Acad Sci USA 2006 10345 16924 16929 (Pubitemid 44737354)
82. Homeobox genes in leukemogenesis. Buske C, Humphries RK, Int J Hematol 2000 71 301 308 10905048
83. Homeobox gene expression plus autocrine growth factor production elicits myeloid leukemia. Perkins A, Kongsuwan K, Visvader J, Adams JM, Cory S, Proc Natl Acad Sci USA 1990 87 8398 8402 10.1073/pnas.87.21.8398 1978323
84. The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis. Scholl C, Bansal D, Döhner K, Eiwen K, Huntly BJ, Lee BH, Rücker FG, Schlenk RF, Bullinger L, Döhner H, Gilliland DG, Fröhling S, J Clin Invest 2007 117 1037 1048 10.1172/JCI30182 17347684 (Pubitemid 46556760)
85. CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARγ signaling. Faber K, Bullinger L, Ragu C, Garding A, Mertens D, Miller C, Martin D, Walcher D, Döhner K, Döhner H, Claus R, Plass C, Sykes SM, Lane SW, Scholl C, Fröhling S, J Clin Invest 2013 123 299 314 10.1172/JCI64745 23202735
86. Fusion of the nucleoporin gene NUP98 to HoxA9 by the chromosome translocation t(7, 11)(p15;p15) in human myeloid leukemia. Nakamura T, Largaespada DA, Lee MP, Johnson LA, Ohyashiki K, Toyama K, Chen SJ, Willman CL, Chen IM, Feinberg AP, Jenkins NA, Copeland NG, Shaughnessy JD Jr, Nat Genet 1996 12 154 158 10.1038/ng0296-154 8563753 (Pubitemid 26051295)
87. The t(7;11)(p15;p15) translocation in acute myeloid leukemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HoxA9. Borrow J, Shearman AM, Stanton VP, Becher R, Collins T, Williams Chen IM, Feinberg AP, Jenkins NA, Copeland NG, Shaughnessy JD, Nat Genet 1996 12 159 167 10.1038/ng0296-159 8563754 (Pubitemid 26051296)
88. Overexpression of HoxB3 in hematopoietic cells causes defective lymphoid development and progressive myeloproliferation. Sauvageau G, Thorsteinsdottir U, Hough MR, Hugo P, Lawrence HJ, Largman C, Humphreys RK, Immunity 1997 6 13 22 10.1016/S1074-7613(00)80238-1 9052833 (Pubitemid 27130211)
89. HoxB4-Induced Expansion of Adult Hematopoietic Stem Cells Ex Vivo. Antonchuk J, Sauvageau G, Humphries RK, Cell 2002 109 39 45 10.1016/S0092- 8674(02)00697-9 11955445 (Pubitemid 34327515)
90. Overexpression of HoxA10 in murine hematopoietic cells perturbs both myeloid and lymphoid differentiation and leads to acute myeloid leukemia. Thorsteinsdottir U, Sauvageau G, Hough MR, Dragowska W, Lansdorp PM, Lawrence HJ, Largman C, Humphries RK, Mol Cell Biol 1997 17 495 505 8972230 (Pubitemid 26425639)
91. Overexpression of the myeloid leukemia-associated HoxA9 gene in bone marrow cells induces stem cell expansion. Thorsteinsdottir U, Mamo A, Kroon E, Jerome L, Bijl J, Lawrence HJ, Humphries RK, Sauvageau G, Blood 2002 99 121 129 10.1182/blood.V99.1.121 11756161 (Pubitemid 34532973)
92. Cdx4 dysregulates Hox gene expression and generates acute myeloid leukemia alone and in cooperation with Meis1a in a murine model. Bansal D, Scholl C, Fröhling S, McDowell E, Lee BH, Döhner K, Ernst P, Davidson AJ, Daley GQ, Zon LI, Gilliland DG, Huntly BJ, Proc Natl Acad Sci USA 2006 103 16924 169249 10.1073/pnas.0604579103 17068127 (Pubitemid 44737354)
93. HoxA9 gene expression in the chronic myeloid leukemia progression. Tedeschi FA, Zalazar FE, Leuk Res 2006 30 1453 1456 10.1016/j.leukres.2006.02. 022 16630659 (Pubitemid 44307320)
94. HoxA9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. Kroon E, Krosl J, Thorsteinsdottir U, Baban S, Buchberg AM, Sauvageau G, EMBO J 1998 17 3714 3725 10.1093/emboj/17.13.3714 9649441 (Pubitemid 28327389)
95. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Zuber J, Rappaport AR, Lo W, Wang E, Chen C, Vaseva AV, Shi J, Weissmueller S, Fellmann C, Taylor MJ, Weissenboeck M, Graeber TG, Kogan SC, Vakoc CR, Lowe SW, Genes Dev 2011 25 1628 40 10.1101/gad.17269211 21828272
96. The diverse functions of Dot1 and H3K79 methylation. Nyguyen AT, Zhang Y, Genes Dev 2011 25 1345 1358 10.1101/gad.2057811 21724828
97. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, Johnston LD, Scott MP, Smith JJ, Xiao Y, Jin L, Kuntz KW, Chesworth R, Moyer MP, Bernt KM, Tseng JC, Kung AL, Armstrong SA, Copeland RA, Richon VM, Pollock RM, Cancer Cell 2011 20 53 65 10.1016/j.ccr.2011.06.009 21741596
98. Targeting epigenetic programs in MLL-rearranged leukemias. Bernt KM, Armstrong SA, Hematol Am Soc Hematol Educ Program 2011 2011 354 360 10.1182/asheducation-2011.1.354
99. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Matsunaga T, Takemoto N, Sato T, Takimoto R, Tanaka I, Fujimi A, Akiyama T, Kuroda H, Kawano Y, Kobune M, Kato J, Hirayama Y, Sakamaki S, Kohda K, Miyake K, Niitsu Y, Nat Med 2003 9 1158 1165 10.1038/nm909 12897778 (Pubitemid 37173700)
100. Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia. Matsunaga T, Fukai F, Miura S, Nakane Y, Owaki T, Kodama H, Tanaka M, Nagaya T, Takimoto R, Takayama T, Niitsu Y, Leukemia 2008 22 353 360 10.1038/sj.leu.2405017 17972943 (Pubitemid 351250540)
101. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK, Prior JL, Piwnica-Worms D, Bridger G, Ley TJ, DiPersio JF, Blood 2009 113 6206 14 10.1182/blood-2008-06-162123 19050309
102. Berberine inhibits SDF-1-induced AML cells and leukemic stem cells migration via regulation of SDF-1 level in bone marrow stromal cells. Li H, Guo L, Jie S, Liu W, Liu W, Zhu J, Du W, Fan L, Wang X, Fu B, Huang S, Biomed Pharmocother 2008 62 573 578 10.1016/j.biopha.2008.08.003
103. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE, Nat Med 2006 10 1167 1174 (Pubitemid 44527352)
104. Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression. Sengupta A, Banerjee D, Chandra S, Banerji SK, Ghosh R, Roy R, Banerjee S, Leukemia 2007 21 949 955 17361218 (Pubitemid 46672071)
105. HoxA10 is a critical regulator for hematopoietic stem cells and erythroid/megakaryocyte development. Magnusson M, Brun AC, Miyake N, Blood 2007 109 3687 3696 10.1182/blood-2006-10-054676 17234739 (Pubitemid 46641717)
106. Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to forkhead box O-mediated transcription. Almeida M, Han L, Martin-Millan M, O'Brien CA, Manolagas SC, J Biol Chem 2007 282 27298 27305 10.1074/jbc.M702811200 17623658 (Pubitemid 47501978)
107. ADAM10 cleavage of N-cadherin and regulation of cell-cell adhesion and beta-catenin nuclear signaling. Reiss K, Maretzky T, Ludwig A, Tousseyn T, de Strooper B, Hartmann D, Saftig P, EMBO J 2005 24 742 752 10.1038/sj.emboj. 7600548 15692570 (Pubitemid 40396104)
108. CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression. Schürch C, Riether C, Matter MS, Tzankov A, Ochsenbein AF, J Clin Invest 2012 122 624 638 10.1172/JCI45977 22232214
109. A role for GPx3 in activity of normal and leukemia stem cells. Herault O, Hope KJ, Deneault E, Mayotte N, Chagraoui J, Wilhelm BT, Cellot S, Sauvageau M, Andrade-Navarro MA, Hébert J, Sauvageau G, J Exp Med 2012 209 895 901 10.1084/jem.20102386 22508837
110. AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H, Brumme KM, Acharya SS, Scholl C, Tothova Z, Attar EC, Fröhling S, DePinho RA, Armstrong SA, Gilliland DG, Scadden DT, Cell 2011 14 697 708
111. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Abrahamsson AE, Geron I, Gotlib J, Dao KH, Barroga CF, Newton IG, Giles FJ, Durocher J, Creusot RS, Karimi M, Jones C, Zehnder JL, Keating A, Negrin RS, Weissman IL, Jamieson CH, Proc Natl Acad Sci USA 2009 106 3925 3929 10.1073/pnas.0900189106 19237556
112. GSK3 regulates the expressions of human and mouse c-Myb via different mechanisms. Kitagawa K, Kotake Y, Hiramatsu Y, Liu N, Suzuki S, Nakamura S, Kikuchi A, Kitagawa M, Cell Div 2010 5 27 10.1186/1747-1028-5-27 21092141
113. GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. Wang Z, Iwasaki M, Ficara F, Lin C, Matheny C, Wong SH, Smith KS, Cleary ML, Cancer Cell 2010 17 597 608 10.1016/j.ccr.2010.04.024 20541704